Corona Remedies IPO Day 1: Check Subscription Status, Key Highlights, and More
India-focused branded pharmaceutical formulation company Corona Remedies has launched its Initial Public Offering (IPO) today, December 8, 2025. Prior to the IPO opening, the company raised ₹195 crore from 15 anchor investors on December 5, 2025.
Corona Remedies IPO: Issue Details
The Corona Remedies IPO is a book-building issue of ₹655.37 crore, consisting entirely of an offer for sale (OFS) of 0.62 crore shares.
The price band is set between ₹1008 and ₹1062 per share. The basis of allotment will be finalised by December 11, 2025, and the tentative listing date on BSE and NSE is December 15, 2025.
Corona Remedies IPO Day 1 Subscription Status
[8-December-2025 11:27:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.22 |
|
Non-Institutional Investors |
0.32 |
|
Retail Individual Investors (RIIs) |
0.32 |
|
Employees |
0.44 |
|
Total |
0.21 |
Utilisation of IPO Proceeds
As the issue is entirely an offer for sale, the company will not receive any proceeds, and they will directly be allocated to selling shareholders.
Corona Remedies Business Overview
Corona Remedies is a pharmaceutical company engaged in the development, manufacturing, and marketing of branded formulations across key therapeutic categories, including women’s health, cardio-diabetes, pain and musculoskeletal care, urology, and a range of multispecialty segments.
The company’s product portfolio as of June 30, 2025, comprises 71 brands spanning established and emerging therapeutic areas.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.